|Back||Reported Adverse Drug Reaction Cases|
|Tumour necrosis factor alpha inhibitors|
Tumour necrosis factor alpha (TNFΑ) is a cellular protein produced by the immune system and is an important mediator of many diseases, including inflammatory arthritis and inflammatory bowel disease. Currently, three TNFΑ blocking agents are registered in Australia: infliximab (Remicade) - for the treatment of Crohn's disease, rheumatoid arthritis and ankylosing spondylitis; etanercept (Enbrel) - for rheumatoid arthritis, polyarticular juvenile chronic arthritis, psoriatic arthritis and ankylosing spondylitis; and adalimumab (Humira) - for rheumatoid arthritis.
While extremely effective, TNFΑ inhibitors are associated with several serious reactions.1,2,3 These include:
ADRAC has received 319 reports involving TNFΑ inhibitors since 2000. The more serious of these are: malignant melanoma (3 reports), lymphoma (5), tuberculosis (4), pneumonia/lower respiratory tract infections (23), sepsis (10), lupus or lupus-like syndrome (22) and anaphylaxis (9). According to Medicare Australia statistics, 57,846 prescriptions for the three TNFΑ inhibitors combined have been issued for the treatment of rheumatoid arthritis since 2000.
Given their mechanisms of action, it is possible that the use of TNFΑ inhibitors may predispose patients to an increased risk of malignancies or accelerate their development. A recent meta-analysis of randomised trials of infliximab or adalimumab in rheumatoid arthritis found that malignancies developed in 29/3192 (0.9%) patients treated with infliximab or adalimumab, compared with 3/1428 (0.2%) patients given placebo.4 The risk of malignancies was not different from placebo with low dose TNFΑ inhibitors but was 4 fold greater with high doses of infliximab or adalimumab.4 An increased risk of malignancies has also been reported for etanercept.
The Australian Product Information for these medicines advises prescribers that caution should be exercised when considering TNF-blocking therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop a malignancy.
The recent meta-analysis also showed a 2-fold increased risk of serious infections with TNFΑ inhibitors, regardless of dose. Patients receiving TNFΑ inhibitors should not receive concurrent vaccination with live vaccines and consideration should be given to screening patients for pre-existing infections, particularly hepatitis B and tuberculosis, prior to their use.5Reference
Australian Adverse Drug Reactions Bulletin, Volume 25, Number 6, December 2006
» Latest Notification
» New Drugs
» Import of Drugs
» Drug Prices
|» Applications Forms
» Forms & Fees
» Licence Conditions
» Health, Pharma. Policies & Reports
» Govt. Bodies
» Information Centre
|» Regulatory News
» Research News
» News in Hindi
» Contact Us
DrugsControl.org - Jaipur, INDIA. All Rights Reserved |
||Site last updated: December 30, 1899 at|